Virologica Sinica

, Volume 29, Issue 6, pp 327–342 | Cite as

Ocular herpes: the pathophysiology, management and treatment of herpetic eye diseases

Open Access
Review

Abstract

Herpesviruses are a prominent cause of human viral disease, second only to the cold and influenza viruses. Most herpesvirus infections are mild or asymptomatic. However, when the virus invades the eye, a number of pathologies can develop and its associated sequelae have become a considerable source of ocular morbidity. The most common culprits of herpetic eye disease are the herpes simplex virus (HSV), varicella zoster virus (VZV), and cytomegalovirus (CMV). While primary infection can produce ocular disease, the most destructive manifestations tend to arise from recurrent infection. These recurrent infections can wreck devastating effects and lead to irreversible vision loss accompanied by a decreased quality of life, increased healthcare usage, and significant cost burden. Unfortunately, no method currently exists to eradicate herpesviruses from the body after infection. Treatment and management of herpes-related eye conditions continue to revolve around antiviral drugs, although corticosteroids, interferons, and other newer therapies may also be appropriate depending on the disease presentation. Ultimately, the advent of effective vaccines will be crucial to preventing herpesvirus diseases altogether and cutting the incidence of ocular complications.

Keywords

ocular herpes herpetic eye diseases varicella zoster virus (VZV) cytomegalovirus (CMV) herpes simplex virus (HSV) 

References

  1. Akhtar J, Shukla D. 2009. Viral entry mechanisms: cellular and viral mediators of herpes simplex virus entry. FEBS J, 276: 7228–7236.PubMedCentralPubMedGoogle Scholar
  2. Al-Dujaili L J, Clerkin P P, Clement C, McFerrin H E, Bhattacharjee P S, Varnell E D, Kaufman H E, Hill J M. 2011. Ocular herpes simplex virus: how are latency, reactivation, recurrent disease and therapy interrelated? Future Microbiol, 6: 877–907.PubMedCentralPubMedGoogle Scholar
  3. Anderson J R, Behrens C, Binswanger I A, and al. e 2013, posting date. HIV Web Study. http://depts.washington.edu/hivaids/oit/case7/discussion.html.Google Scholar
  4. Arvin A M. 1996. Varicella-zoster virus. Clin Microbiol Rev, 9: 361–381.PubMedCentralPubMedGoogle Scholar
  5. Arvin A M. 2007. Human herpesviruses: biology, therapy, and immunoprophylaxis. Cambridge University Press, Cambridge; New York, pp. 1262–1273.Google Scholar
  6. Azwa A, Barton S E. 2009. Aspects of herpes simplex virus: a clinical review. J Fam Plann Reprod Health Care, 35: 237–242.PubMedGoogle Scholar
  7. Barron B A, Gee L, Hauck W W, Kurinij N, Dawson C R, Jones D B, Wilhelmus K R, Kaufman H E, Sugar J, Hyndiuk R A, Laibson P R, Stulting R D, Asbell P A. 1994. Herpetic Eye Disease Study. A controlled trial of oral acyclovir for herpes simplex stromal keratitis. Ophthalmology, 101: 1871–1882.PubMedGoogle Scholar
  8. Belshe R B, Leone P A, Bernstein D I, Wald A, Levin M J, Stapleton J T, Gorfinkel I, Morrow R L, Ewell M G, Stokes-Riner A, Dubin G, Heineman T C, Schulte J M, Deal C D, Herpevac Trial for Women. 2012. Efficacy results of a trial of a herpes simplex vaccine. N Engl J Med, 366: 34–43.PubMedCentralPubMedGoogle Scholar
  9. Bloom J N, Palestine A G. 1988. The diagnosis of cytomegalovirus retinitis. Ann Intern Med, 109: 963–969.PubMedGoogle Scholar
  10. Bowen E F, Griffiths P D, Davey C C, Emery V C, Johnson M A. 1996. Lessons from the natural history of cytomegalovirus. AIDS, 10Suppl 1: S37–S41.PubMedGoogle Scholar
  11. Bradley H, Markowitz L E, Gibson T, McQuillan G M. 2014. Seroprevalence of herpes simplex virus types 1 and 2—United States, 1999–2010. J Infect Dis, 209: 325–333.PubMedGoogle Scholar
  12. Buxbaum S, Geers M, Gross G, Schofer H, Rabenau H F, Doerr H W. 2003. Epidemiology of herpes simplex virus types 1 and 2 in Germany: what has changed? Med Microbiol Immunol, 192: 177–181.PubMedGoogle Scholar
  13. Caserta M T, Mock D J, Dewhurst S. 2001. Human herpesvirus 6. Clin Infect Dis, 33: 829–833.PubMedGoogle Scholar
  14. Cobo L M, Foulks G N, Liesegang T, Lass J, Sutphin J E, Wilhelmus K, Jones D B, Chapman S, Segreti A C, King D H. 1986. Oral acyclovir in the treatment of acute herpes zoster ophthalmicus. Ophthalmology, 93: 763–770.PubMedGoogle Scholar
  15. Coleman J L, Shukla D. 2013. Recent advances in vaccine development for herpes simplex virus types I and II. Hum Vaccin Immunother, 9: 729–735.PubMedCentralPubMedGoogle Scholar
  16. Colin J, Chastel C, Kaufman H E, Kissling G E. 1987. Combination therapy for dendritic keratitis with acyclovir and vidarabine. J Ocul Pharmacol, 3: 39–42.PubMedGoogle Scholar
  17. Daibata M, Komatsu T, Taguchi H. 2000. Human herpesviruses in primary ocular lymphoma. Leuk Lymphoma, 37: 361–365.PubMedGoogle Scholar
  18. Damato E G, Winnen C W. 2002. Cytomegalovirus infection: perinatal implications. J Obstet Gynecol Neonatal Nurs, 31: 86–92.PubMedGoogle Scholar
  19. Darougar S, Wishart M S, Viswalingam N D. 1985. Epidemiological and clinical features of primary herpes simplex virus ocular infection. Br J Ophthalmol, 69: 2–6.PubMedCentralPubMedGoogle Scholar
  20. Dartt D A, Dana R, D’Amore p, Niederkorn J. 2011. Immunology, Inflammation and Diseases of the Eye. San Diego: Academic Press.Google Scholar
  21. Farhatullah S, Kaza S, Athmanathan S, Garg P, Reddy S B, Sharma S. 2004. Diagnosis of herpes simplex virus-1 keratitis using Giemsa stain, immunofluorescence assay, and polymerase chain reaction assay on corneal scrapings. Br J Ophthalmol, 88: 142–144.PubMedCentralPubMedGoogle Scholar
  22. Farooq A V, Shukla D. 2012. Herpes simplex epithelial and stromal keratitis: an epidemiologic update. Surv Ophthalmol, 57: 448–462.PubMedCentralPubMedGoogle Scholar
  23. Farooq A V, Shah A, Shukla D. 2010. The role of herpesviruses in ocular infections. Virus Adaptation and Treatment, 2: 115–123.Google Scholar
  24. Fulop T, Larbi A, Pawelec G. 2013. Human T cell aging and the impact of persistent viral infections. Front Immunol, 4: 271.PubMedCentralPubMedGoogle Scholar
  25. Gershon A A, Gershon M D. 2010. Perspectives on vaccines against varicella-zoster virus infections. Curr Top Microbiol Immunol, 342: 359–372.PubMedGoogle Scholar
  26. Gilden D H, Dueland A N, Devlin M E, Mahalingam R, Cohrs R. 1992. Varicella-zoster virus reactivation without rash. J Infect Dis, 166 Suppl 1: S30–S34.Google Scholar
  27. Gimenez F, Suryawanshi A, Rouse B T. 2013. Pathogenesis of herpes stromal keratitis—a focus on corneal neovascularization. Prog Retin Eye Res, 33: 1–9.PubMedCentralPubMedGoogle Scholar
  28. Green L K, Pavan-Langston D. 2006. Herpes simplex ocular inflammatory disease. Int Ophthalmol Clin, 46: 27–37.PubMedGoogle Scholar
  29. Gross G, Schofer H, Wassilew S, Friese K, Timm A, Guthoff R, Pau H W, Malin J P, Wutzler P, Doerr H W. 2003. Herpes zoster guideline of the German Dermatology Society (DDG). J Clin Virol, 26: 277–289.PubMedGoogle Scholar
  30. Guess S, Stone D U, Chodosh J. 2007. Evidence-based treatment of herpes simplex virus keratitis: a systematic review. Ocul Surf, 5: 240–250.PubMedGoogle Scholar
  31. Hamrah P, Sahin A, Dastjerdi M H, Shahatit B M, Bayhan H A, Dana R, Pavan-Langston D. 2012. Cellular changes of the corneal epithelium and stroma in herpes simplex keratitis: an in vivo confocal microscopy study. Ophthalmology, 119: 1791–1797.PubMedCentralPubMedGoogle Scholar
  32. Hennis H L, Scott A A, Apple D J. 1989. Cytomegalovirus retinitis. Surv Ophthalmol, 34: 193–203.PubMedGoogle Scholar
  33. Hori J. 2008. Mechanisms of immune privilege in the anterior segment of the eye: what we learn from corneal transplantation. J Ocul Biol Dis Infor, 1: 94–100.PubMedCentralPubMedGoogle Scholar
  34. Hung S O, Patterson A, Rees P J. 1984. Pharmacokinetics of oral acyclovir (Zovirax) in the eye. Br J Ophthalmol, 68: 192–195.PubMedCentralPubMedGoogle Scholar
  35. Hwang C W, Jr., Steigleman W A, Saucedo-Sanchez E, Tuli S S. 2013. Reactivation of herpes zoster keratitis in an adult after varicella zoster vaccination. Cornea, 32: 508–509.PubMedGoogle Scholar
  36. Kahloun R, Attia S, Jelliti B, Attia A Z, Khochtali S, Yahia S B, Zaouali S, Khairallah M. 2014. Ocular involvement and visual outcome of herpes zoster ophthalmicus: review of 45 patients from Tunisia, North Africa. J Ophthalmic Inflamm Infect, 4: 25.PubMedCentralPubMedGoogle Scholar
  37. Karsten E, Watson S L, Foster L J. 2012. Diversity of microbial species implicated in keratitis: a review. Open Ophthalmol J, 6: 110–124.PubMedCentralPubMedGoogle Scholar
  38. Kaufman H E. 1962. Clinical cure of herpes simplex keratitis by 5-iodo-2-deoxyuridine. Proc Soc Exp Biol Med, 109: 251–252.PubMedGoogle Scholar
  39. Keating G M. 2013. Shingles (herpes zoster) vaccine (zostavax(®)): a review of its use in the prevention of herpes zoster and postherpetic neuralgia in adults aged ≥50 years. Drugs, 73: 1227–1244.PubMedGoogle Scholar
  40. Kim S R, Khan F, Ramirez-Fort M K, Downing C, Tyring S K. 2014. Varicella zoster: an update on current treatment options and future perspectives. Expert Opin Pharmacother, 15: 61–71.PubMedGoogle Scholar
  41. Knickelbein J E, Hendricks R L, Charukamnoetkanok P. 2009. Management of herpes simplex virus stromal keratitis: an evidence-based review. Surv Ophthalmol, 54: 226–234.PubMedGoogle Scholar
  42. Kwong A D, Frenkel N. 1987. Herpes simplex virus-infected cells contain a function(s) that destabilizes both host and viral mRNAs. Proc Natl Acad Sci USA, 84: 1926–1930.PubMedCentralPubMedGoogle Scholar
  43. Labetoulle M, Auquier P, Conrad H, Crochard A, Daniloski M, Bouee S, El Hasnaoui A, Colin J. 2005. Incidence of herpes simplex virus keratitis in France. Ophthalmology, 112: 888–895.PubMedGoogle Scholar
  44. Lairson D R, Begley C E, Reynolds T F, Wilhelmus K R. 2003. Prevention of herpes simplex virus eye disease: a cost-effectiveness analysis. Arch Ophthalmol, 121: 108–112.PubMedGoogle Scholar
  45. Liesegang T J. 1992. Biology and molecular aspects of herpes simplex and varicella-zoster virus infections. Ophthalmology, 99: 781–799.PubMedGoogle Scholar
  46. Liesegang T J. 2008. Herpes zoster ophthalmicus natural history, risk factors, clinical presentation, and morbidity. Ophthalmology, 115: S3–S12.PubMedGoogle Scholar
  47. Liesegang T J, Melton L J, 3rd, Daly P J, Ilstrup D M. 1989. Epidemiology of ocular herpes simplex. Incidence in Rochester, Minn, 1950 through 1982. Arch Ophthalmol, 107: 1155–1159.PubMedGoogle Scholar
  48. Liu S, Pavan-Langston D, Colby K A. 2012. Pediatric herpes simplex of the anterior segment: characteristics, treatment, and outcomes. Ophthalmology, 119: 2003–2008.PubMedGoogle Scholar
  49. Matoba A Y. 1990. Ocular disease associated with Epstein-Barr virus infection. Surv Ophthalmol, 35: 145–150.PubMedGoogle Scholar
  50. Matsuo T, Itami M. 2002. Seropositivity of human herpesvirus-8 in patients with uveitis. Ocul Immunol Inflamm, 10: 197–199.PubMedGoogle Scholar
  51. Mechai F, Boutolleau D, Manceron V, Gasnault J, Quertainmont Y, Brosseau J P, Delfraissy J F, Labetoulle M, and Goujard C. 2007. Human herpesvirus 6-associated retrobulbar optic neuritis in an HIV-infected patient: response to anti-herpesvirus therapy and long-term outcome. J Med Virol, 79: 931–934.PubMedGoogle Scholar
  52. Murray P R, Rosenthal K S, Pfaller M A. 2005. Human Herpesviruses Medical microbiology, 5th ed. Philadelphia: Elsevier Mosby, pp. 461–484.Google Scholar
  53. Musch D C, Martin D F, Gordon J F, Davis M D, Kuppermann B D. 1997. Treatment of cytomegalovirus retinitis with a sustained-release ganciclovir implant. The Ganciclovir Implant Study Group. N Engl J Med, 337: 83–90.Google Scholar
  54. Newman H, Gooding C. 2013. Viral ocular manifestations: a broad overview. Rev Med Virol, 23: 281–294.PubMedGoogle Scholar
  55. Nguyen L H, Knipe D M, Finberg R W. 1992. Replication-defective mutants of herpes simplex virus (HSV) induce cellular immunity and protect against lethal HSV infection. J Virol, 66: 7067–7072.PubMedCentralPubMedGoogle Scholar
  56. Nguyen Q D, Kempen J H, Bolton S G, Dunn J P, Jabs D A. 2000. Immune recovery uveitis in patients with AIDS and cytomegalovirus retinitis after highly active antiretroviral therapy. Am J Ophthalmol, 129: 634–639.PubMedGoogle Scholar
  57. Nilsen A, Myrmel H. 2000. Changing trends in genital herpes simplex virus infection in Bergen, Norway. Acta Obstet Gynecol Scand, 79: 693–696.PubMedGoogle Scholar
  58. Ogata N, Koike N, Yoshikawa T, Takahashi K. 2011. Human herpesvirus 6-associated uveitis with optic neuritis diagnosed by multiplex PCR. Jpn J Ophthalmol, 55: 502–505.PubMedGoogle Scholar
  59. Ohara P T, Chin M S, LaVail J H. 2000. The spread of herpes simplex virus type 1 from trigeminal neurons to the murine cornea: an immunoelectron microscopy study. J Virol, 74: 4776–4786.PubMedCentralPubMedGoogle Scholar
  60. Opstelten W, Zaal M J. 2005. Managing ophthalmic herpes zoster in primary care. BMJ, 331: 147–151.PubMedCentralPubMedGoogle Scholar
  61. Oxman M N, Levin M J, Johnson G R, Schmader K E, Straus S E, Gelb L D, Arbeit R D, Simberkoff M S, Gershon A A, Davis L E, Weinberg A, Boardman K D, Williams H M, Zhang J H, Peduzzi P N, Beisel C E, Morrison V A, Guatelli J C, Brooks P A, Kauffman C A, Pachucki C T, Neuzil K M, Betts R F, Wright P F, Griffin M R, Brunell P, Soto N E, Marques A R, Keay S K, Goodman R P, Cotton D J, Gnann J W, Jr., Loutit J, Holodniy M, Keitel W A, Crawford G E, Yeh S S, Lobo Z, Toney J F, Greenberg R N, Keller P M, Harbecke R, Hayward A R, Irwin M R, Kyriakides T C, Chan C Y, Chan I S, Wang W W, Annunziato P W, Silber J L, Shingles Prevention Study G. 2005. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med, 352: 2271–2284.PubMedGoogle Scholar
  62. Palestine A G. 1988. Clinical aspects of cytomegalovirus retinitis. Rev Infect Dis, 10Suppl 3: S515–S521.PubMedGoogle Scholar
  63. Papaloukas O, Giannouli G, Papaevangelou V. 2014. Successes and challenges in varicella vaccine. Ther Adv Vaccines, 2: 39–55.PubMedCentralPubMedGoogle Scholar
  64. Pepose J S, Keadle T L, Morrison L A. 2006. Ocular herpes simplex: changing epidemiology, emerging disease patterns, and the potential of vaccine prevention and therapy. Am J Ophthalmol, 141: 547–557.PubMedGoogle Scholar
  65. Centers for Disease Control and Prevention. 2012. Epidemiology and Prevention of Vaccine-Preventable Diseases. Atkinson W, Wolfe S, Hamborsky J, eds. 12th ed., second printing. Washington DC: Public Health Foundation, pp301–324.Google Scholar
  66. Prober C G, Kirk L E, Keeney R E. 1982. Acyclovir therapy of chickenpox in immunosuppressed children—a collaborative study. J Pediatr, 101: 622–625.PubMedGoogle Scholar
  67. Rabenau H F, Buxbaum S, Preiser W, Weber B, Doerr H W. 2002. Seroprevalence of herpes simplex virus types 1 and type 2 in the Frankfurt am Main area, Germany. Med Microbiol Immunol, 190: 153–160.PubMedGoogle Scholar
  68. Revere K, Davidson S L. 2013. Update on management of herpes keratitis in children. Curr Opin Ophthalmol, 24: 343–347.PubMedGoogle Scholar
  69. Rocha G, Muzychuk M. 2010. Herpes Zoster Ophthalmicus: More than meets the eye. Clinical & Surgical Ophthalmology, 28: 11–16.Google Scholar
  70. Rowe A M, St Leger A J, Jeon S, Dhaliwal D K, Knickelbein J E, Hendricks R L. 2013. Herpes keratitis. Prog Retin Eye Res, 32: 88–101.PubMedGoogle Scholar
  71. Roy F H, Fraunfelder F W, Fraunfelder F T. 2008. Roy and Fraunfelder’s Current Ocular Therapy. Elsevier Saunders.Google Scholar
  72. Sacchetti M, Lambiase A. 2014. Diagnosis and management of neurotrophic keratitis. Clin Ophthalmol, 8: 571–579.PubMedCentralPubMedGoogle Scholar
  73. Schmader K, Gnann J W, Jr., Watson C P. 2008. The epidemiological, clinical, and pathological rationale for the herpes zoster vaccine. J Infect Dis, 197Suppl 2: S207–S215.PubMedGoogle Scholar
  74. Schreiber A, Harter G, Schubert A, Bunjes D, Mertens T, Michel D. 2009. Antiviral treatment of cytomegalovirus infection and resistant strains. Expert Opin Pharmacother, 10: 191–209.PubMedGoogle Scholar
  75. Scoular A, Norrie J, Gillespie G, Mir N, Carman W F. 2002. Longitudinal study of genital infection by herpes simplex virus type 1 in Western Scotland over 15 years. BMJ, 324: 1366–1367.PubMedCentralPubMedGoogle Scholar
  76. Shaikh S, Ta C N. 2002. Evaluation and management of herpes zoster ophthalmicus. Am Fam Physician, 66: 1723–1730.PubMedGoogle Scholar
  77. Simberkoff M S, Arbeit R D, Johnson G R, Oxman M N, Boardman K D, Williams H M, Levin M J, Schmader K E, Gelb L D, Keay S, Neuzil K, Greenberg R N, Griffin M R, Davis L E, Morrison V A, Annunziato P W, Shingles Prevention Study G. 2010. Safety of herpes zoster vaccine in the shingles prevention study: a randomized trial. Ann Intern Med, 152: 545–554.PubMedGoogle Scholar
  78. Slobod K S, Sandlund J T, Spiegel P H, Haik B, Hurwitz J L, Conley M E, Bowman L C, Benaim E, Jenkins J J, Stocks R M, Gan Y, Sixbey J W. 2000. Molecular evidence of ocular Epstein-Barr virus infection. Clin Infect Dis, 31: 184–188.PubMedGoogle Scholar
  79. Smith J S, Robinson N J. 2002. Age-specific prevalence of infection with herpes simplex virus types 2 and 1: a global review. J Infect Dis, 186Suppl 1: S3–S28.PubMedGoogle Scholar
  80. Stanberry L R, Spruance S L, Cunningham A L, Bernstein D I, Mindel A, Sacks S, Tyring S, Aoki F Y, Slaoui M, Denis M, Vandepapeliere P, Dubin G, GlaxoSmithKline Herpes Vaccine Efficacy Study G. 2002. Glycoprotein-D-adjuvant vaccine to prevent genital herpes. N Engl J Med, 347: 1652–1661.PubMedGoogle Scholar
  81. Stein-Streilein J. 2008. Immune regulation and the eye. Trends Immunol, 29: 548–554.PubMedGoogle Scholar
  82. Steiner I, Kennedy P G, Pachner A R. 2007. The neurotropic herpes viruses: herpes simplex and varicella-zoster. Lancet Neurol, 6: 1015–1028.PubMedGoogle Scholar
  83. Stewart M W. 2010. Optimal management of cytomegalovirus retinitis in patients with AIDS. Clin Ophthalmol, 4: 285–299.PubMedCentralPubMedGoogle Scholar
  84. Sundmacher R. 2009. Color atlas of herpetic eye disease: a practical guide to clinical management. Berlin: Springer, pp. 51–56.Google Scholar
  85. Sung H, Schleiss M R. 2010. Update on the current status of cytomegalovirus vaccines. Expert Rev Vaccines, 9: 1303–1314.PubMedCentralPubMedGoogle Scholar
  86. Suzuki T, Ohashi Y. 2008. Corneal endotheliitis. Semin Ophthalmol, 23: 235–240.PubMedGoogle Scholar
  87. Tappuni A R. 2011. Immune reconstitution inflammatory syndrome. Adv Dent Res, 23: 90–96.PubMedGoogle Scholar
  88. Tasman W, Jaeger E A. 2013. Duane’s ophthalmology on DVD-ROM-2013 edition. http://80.36.73.149/almacen/medicina/oftalmologia/enciclopedias/duane/pages/v3c028a.html.Google Scholar
  89. Toma H S, Murina A T, Areaux R G, Jr., Neumann D M, Bhattacharjee P S, Foster T P, Kaufman H E, Hill J M. 2008. Ocular HSV-1 latency, reactivation and recurrent disease. Semin Ophthalmol, 23: 249–273.PubMedGoogle Scholar
  90. Tran T, Druce J D, Catton M C, Kelly H, Birch C J. 2004. Changing epidemiology of genital herpes simplex virus infection in Melbourne, Australia, between 1980 and 2003. Sex Transm Infect, 80: 277–279.PubMedCentralPubMedGoogle Scholar
  91. Tyring S K. 2006. Mucosal immunology and virology. Springer, London, pp.179–189.Google Scholar
  92. Tyring S K. 2007. Management of herpes zoster and postherpetic neuralgia. J Am Acad Dermatol, 57: S136–S142.PubMedGoogle Scholar
  93. Varani S, Landini M P. 2011. Cytomegalovirus-induced immunopathology and its clinical consequences. Herpesviridae, 2: 6.PubMedCentralPubMedGoogle Scholar
  94. Varani S, Spezzacatena P, Manfredi R, Chiodo F, Mastroianni A, Ballarini P, Boschini A, Lazzarotto T, Landini M P. 2000. The incidence of cytomegalovirus (CMV) antigenemia and CMV disease is reduced by highly active antiretroviral therapy. Eur J Epidemiol, 16: 433–437.PubMedGoogle Scholar
  95. Weinberg A, Zhang J H, Oxman M N, Johnson G R, Hayward A R, Caulfield M J, Irwin M R, Clair J, Smith J G, Stanley H, Marchese R D, Harbecke R, Williams H M, Chan I S, Arbeit R D, Gershon A A, Schodel F, Morrison V A, Kauffman C A, Straus S E, Schmader K E, Davis L E, Levin M J, US Department of Veterans Affairs (VA) Cooperative Studies Program Shingles Prevention Study Investigators. 2009. Varicella-zoster virus-specific immune responses to herpes zoster in elderly participants in a trial of a clinically effective zoster vaccine. J Infect Dis, 200: 1068–1077.PubMedCentralPubMedGoogle Scholar
  96. Wenkel H, Rummelt V, Fleckenstein B, Naumann G O. 1998. Detection of varicella zoster virus DNA and viral antigen in human eyes after herpes zoster ophthalmicus. Ophthalmology, 105: 1323–1330.PubMedGoogle Scholar
  97. Whitcup S M. 2000. Cytomegalovirus retinitis in the era of highly active antiretroviral therapy. JAMA, 283: 653–657.PubMedGoogle Scholar
  98. Wilhelmus K R. 2010. Antiviral treatment and other therapeutic interventions for herpes simplex virus epithelial keratitis. Cochrane Database Syst Rev, 12: CD002898.PubMedGoogle Scholar
  99. Wilhelmus K R, Falcon M G, Jones B R. 1981. Bilateral herpetic keratitis. Br J Ophthalmol, 65: 385–387.PubMedCentralPubMedGoogle Scholar
  100. Wong R W, Jumper J M, McDonald H R, Johnson R N, Fu A, Lujan B J, Cunningham E T Jr. 2013. Emerging concepts in the management of acute retinal necrosis. Br J Ophthalmol, 97: 545–552.PubMedGoogle Scholar
  101. Xu F, Sternberg M R, Kottiri B J, McQuillan G M, Lee F K, Nahmias A J, Berman S M, Markowitz L E. 2006. Trends in herpes simplex virus type 1 and type 2 seroprevalence in the United States. JAMA, 296: 964–973.PubMedGoogle Scholar
  102. Yawn B P, Wollan P C, St Sauver J L, Butterfield L C. 2013. Herpes zoster eye complications: rates and trends. Mayo Clin Proc, 88: 562–570.PubMedCentralPubMedGoogle Scholar
  103. Yen M, Ausayakhun S, Chen J, Ausayakhun S, Jirawison C, Heiden D, Holland G N, Margolis T P, Keenan J D. 2014. Telemedicine diagnosis of cytomegalovirus retinitis by nonophthalmologists. JAMA Ophthalmol, 132: 1052–1058.PubMedGoogle Scholar

Copyright information

© Wuhan Institute of Virology, CAS and Springer-Verlag Berlin Heidelberg 2014

Authors and Affiliations

  1. 1.Department of Microbiology, Biochemistry & Molecular Genetics RutgersRutgers — New Jersey Medical SchoolNewarkUSA

Personalised recommendations